Literature DB >> 23065462

Update on the sexual impact of treatment for benign prostatic hyperplasia.

John Roger Bell1, Eric Laborde.   

Abstract

There is an established link between lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). The medical and surgical management of LUTS can affect erectile function (EF), cause ejaculatory dysfunction (EjD) or affect libido. This article will review the effects of these therapies on sexual function.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23065462     DOI： 10.1007/s11934-012-0278-5

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  51 in total

Review 1.  A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Mauro Gacci; Giovanni Corona; Matteo Salvi; Linda Vignozzi; Kevin T McVary; Steven A Kaplan; Claus G Roehrborn; Sergio Serni; Vincenzo Mirone; Marco Carini; Mario Maggi
Journal:  Eur Urol       Date:  2012-02-25       Impact factor: 20.096

2.  Update on AUA guideline on the management of benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

3.  Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Jed C Kaminetsky; Stephen M Auerbach; Barton Wachs; Jay M Young; Anne Esler; Gregory D Sides; Bela S Denes
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

4.  A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years.

Authors:  Liam C Wilson; Peter J Gilling; Andrew Williams; Katie M Kennett; Chris M Frampton; Andre M Westenberg; Mark R Fraundorfer
Journal:  Eur Urol       Date:  2006-05-02       Impact factor: 20.096

5.  Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Henry H Woo; Damien M Bolton; Eric Laborde; Greg Jack; Peter T Chin; Prem Rashid; Jeffrey Thavaseelan; Kevin T McVary
Journal:  J Sex Med       Date:  2011-12-16       Impact factor: 3.802

Review 6.  5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.

Authors:  J Dörsam; J Altwein
Journal:  Prostate Cancer Prostatic Dis       Date:  2008-11-25       Impact factor: 5.554

7.  Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.

Authors:  Mostafa Elhilali; Mark Emberton; Haim Matzkin; R Jeroen A van Moorselaar; Rudolf Hartung; Niels Harving; Antonio Alcaraz; Guy Vallancien
Journal:  BJU Int       Date:  2006-03       Impact factor: 5.588

8.  Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.

Authors:  Claus G Roehrborn; Kevin T McVary; Albert Elion-Mboussa; Lars Viktrup
Journal:  J Urol       Date:  2008-08-22       Impact factor: 7.450

9.  Ejaculatory dysfunction caused by the new alpha1-blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography.

Authors:  Atsushi Nagai; Ryoei Hara; Teruhiko Yokoyama; Yoshimasa Jo; Tomohiro Fujii; Yoshiyuki Miyaji
Journal:  Int J Urol       Date:  2008-10       Impact factor: 3.369

10.  Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group.

Authors:  J T Andersen; P Ekman; H Wolf; H O Beisland; J E Johansson; M Kontturi; T Lehtonen; K Tveter
Journal:  Urology       Date:  1995-11       Impact factor: 2.649
View more
  7 in total

1.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2013

2.  Ahead of the curve.

Authors:  David B Nash
Journal:  Popul Health Manag       Date:  2013       Impact factor: 2.459

3.  Effect of an employer-sponsored health and wellness program on medical cost and utilization.

Authors:  Hangsheng Liu; Katherine M Harris; Sarah Weinberger; Seth Serxner; Soeren Mattke; Ellen Exum
Journal:  Popul Health Manag       Date:  2012-07-23       Impact factor: 2.459

Review 4.  [Influence of medical BPS treatment on sexual function].

Authors:  T Bschleipfer; M Burkart
Journal:  Urologe A       Date:  2018-12       Impact factor: 0.639

5.  Changes in Erectile Function after Photoselective Vaporization of the Prostate with a 120-W GreenLight High-Performance System Laser: 2-Year Follow-Up.

Authors:  Juhyun Park; Sung Yong Cho; Min Chul Cho; Hyeon Jeong; Hwancheol Son
Journal:  World J Mens Health       Date:  2017-11-16       Impact factor: 5.400

6.  Investigation of prostate resected weight on postoperative sexual dysfunction following transurethral resection of prostate surgery: a population-based study.

Authors:  Fu-Chao Liu; Shih-Jyun Shen; Jr-Rung Lin; Huang-Ping Yu
Journal:  Ther Clin Risk Manag       Date:  2019-01-10       Impact factor: 2.423

7.  Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients.

Authors:  Antonio Alcaraz; Alfredo Rodríguez-Antolín; Joaquín Carballido-Rodríguez; David Castro-Díaz; José Medina-Polo; Jesús M Fernández-Gómez; Vincenzo Ficarra; Joan Palou; Javier Ponce de León Roca; Javier C Angulo; Manuel Esteban-Fuertes; José M Cózar-Olmo; Noemí Pérez-León; José M Molero-García; Antonio Fernández-Pro Ledesma; Francisco J Brenes-Bermúdez; José Manasanch
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.